Production of cheaper alternatives to name brand obesity drugs will stop on Wednesday

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

Read the full post on NPR Topics: Health Care

Sydney Lupkin